Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Novacyt
  6. News
  7. Summary
    ALNOV   FR0010397232

NOVACYT

(ALNOV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Novacyt : 2020 Group Consolidated Accounts

06/22/2021 | 04:49am EDT

!"#$%

&&'()#)#

NOVACYT

!"#$%

&&'()#)#

Opinion

'()& !"#$#$*+!"#$%#$%

24),!.-/2$30,!./1!"0#!#$"*#%!+&,+'(()-#!

BasisforOpinion

Observations

!"#$#$

Justification$0ofourassessments%!"#$'(&%

# $ 1$1 )*+,-" .+,-/

Specificverifications

ResponsibilitiesofManagementandThoseChargedwithGovernancefortheConsolidatedFinancialStatements ' !&"%#$%

!"!"

StatutoryAuditor'sResponsibilitiesfortheAuditoftheConsolidatedFinancialStatements

!"#$%&$%'((+(,)

'* (

-/

.

0

/

11

/

+/ 3

.

0

((

+

2-

.

Disclaimer

Novacyt SA published this content on 22 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 June 2021 08:48:00 UTC.


ę Publicnow 2021
All news about NOVACYT
09/16FTSE 100 Rises on Speculation over UK's Travel Restrictions Removal
DJ
09/16GLOBAL MARKETS LIVE : Thales, Nestlé, Evergrande, AMC, Walmart...
09/16FTSE Rises, THG Shares Fall After 1st Half Loss as Shake-Up Looms
DJ
09/16NOVACYT : Dispute With UK Health Department Threatens To Wipe Out H1 Profit
MT
09/16FTSE Rises, Ashtead Gains After 1Q Profit Boost, Guidance Increase
DJ
09/16Novacyt Says Covid-19 Contract Dispute with UK Health Department Continues
DJ
09/16Novacyt to Revise Down 1st Half Revenue Due to UK Covid-19 Contract Dispute -- Update
DJ
09/16NOVACYT : Proposed accounting treatment of ongoing DHSC dispute in 2021 interim results
PU
09/13NOVACYT : AGM voting
PU
09/08NOVACYT : Company's activity during FY20
PU
More news
Financials
Sales 2021 112 M 131 M 131 M
Net income 2021 70,0 M 82,2 M 82,2 M
Net cash 2021 90,4 M 106 M 106 M
P/E ratio 2021 4,14x
Yield 2021 -
Capitalization 254 M 299 M 299 M
EV / Sales 2021 1,47x
EV / Sales 2022 0,74x
Nbr of Employees 174
Free-Float 99,0%
Chart NOVACYT
Duration : Period :
Novacyt Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVACYT
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus SELL
Number of Analysts 1
Last Close Price 3,60 €
Average target price 4,10 €
Spread / Average Target 13,8%
EPS Revisions
Managers and Directors
Graham David Mullis Chief Executive Officer & Executive Director
James Martin Mccarthy Chief Financial Officer & Director
James Christopher Wakefield Chairman
Reginald A. Trevor Chief Technology Officer
Lisa Henriet Director-Group Operations
Sector and Competitors
1st jan.Capi. (M$)
NOVACYT-63.22%299
MODERNA, INC.335.15%183 498
GILEAD SCIENCES, INC.23.05%89 886
BIONTECH SE333.01%85 255
WUXI APPTEC CO., LTD.33.88%68 592
REGENERON PHARMACEUTICALS33.82%67 216